Provides precision gene-editing analytics and off-target risk assessment services for cell and gene therapy developers
Provides precision gene-editing analytics and off-target risk assessment services for cell and gene therapy developers. Its assays detect, nominate, and confirm gene-editing outcomes to help mitigate therapeutic-development risk and support regulatory confidence. Acquired by MaxCyte in January 2025 and integrated into its Cell & Gene Therapy Services business.